Unknown

Dataset Information

0

Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents.


ABSTRACT: Coronavirus disease 2019 (COVID-19) is a mild to moderate respiratory illness in most children and adolescents, but a small proportion develop severe or critical illness. Although pediatric clinical trials for the treatment of COVID-19 are sparse, there are some available drugs for children and adolescents with severe COVID-19. This review summarizes clinical data focusing on antiviral agents and immunomodulators for COVID-19 treatment. Additionally, the current recommendations for therapeutics for children and adolescents with COVID-19 are discussed. Remdesivir is suggested for pediatric patients with COVID-19 in the following cases: children and adolescents with severe COVID-19 who need supplemental oxygen without mechanical ventilation; adolescents aged ≥12 years and weight of at least 40 kg with COVID-19 who do not require supplemental oxygen and are within 7 days of symptom onset and are at high risk of progression to severe illness. Nirmatrelvir/ritonavir is considered for adolescents aged ≥12 years and weighing at least 40 kg who do not require supplemental oxygen and are within 5 days of symptom onset and are at high risk of progression to severe disease. Corticosteroids are not recommended in children and adolescents with mild to moderate COVID-19. Corticosteroids are recommended in children and adolescents with severe to critical COVID-19.

SUBMITTER: Choi SH 

PROVIDER: S-EPMC9348956 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Therapeutics for the treatment of coronavirus disease 2019 in children and adolescents.

Choi Soo-Han SH   Choi Jae Hong JH   Yun Ki Wook KW  

Clinical and experimental pediatrics 20220627 8


Coronavirus disease 2019 (COVID-19) is a mild to moderate respiratory illness in most children and adolescents, but a small proportion develop severe or critical illness. Although pediatric clinical trials for the treatment of COVID-19 are sparse, there are some available drugs for children and adolescents with severe COVID-19. This review summarizes clinical data focusing on antiviral agents and immunomodulators for COVID-19 treatment. Additionally, the current recommendations for therapeutics  ...[more]

Similar Datasets

| S-EPMC7204737 | biostudies-literature
| S-EPMC9272428 | biostudies-literature
| S-EPMC7584265 | biostudies-literature
| S-EPMC9701636 | biostudies-literature
| S-EPMC11662056 | biostudies-literature
2024-04-22 | GSE202553 | GEO
| S-EPMC9377623 | biostudies-literature
| S-EPMC7488170 | biostudies-literature
| S-EPMC9555575 | biostudies-literature
| S-EPMC8872833 | biostudies-literature